THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...
THIO is presently developed as a third line of treatment for NSCLC for patients that are resistant to checkpoint inhibitors and chemotherapy. About MAIA Biotechnology, Inc. MAIA is a targeted ...
The THIO-101 study in 3L will enroll up to 48 ... please visit ClinicalTrials.gov using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology ...
MAIA Biotechnology (MAIA) announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer NSCLC . Following successful outcomes to date in THIO-101 ...
MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...
MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...
CHICAGO, February 26, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer (NSCLC).
CHICAGO, February 26, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback